The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Milestones in Parkinson's disease therapeutics
Abstract
In the mid‐1980s, the treatment of Parkinson's disease was quite exclusively centered on dopatherapy and was focusing on dopamine systems and motor symptoms. A few dopamine agonists and a monoamine oxidase B inhibitor (selegiline) were used as adjuncts in advanced Parkinson's disease. In the early 2010s, levodopa remains the gold standard. New insights into the organization of the basal ganglia paved the way for deep brain stimulation, especially of the subthalamic nucleus, providing spectacular improvement of drug‐refractory levodopa‐induced motor complications. Novel dopamine agonists (pramipexole, ropinirole, rotigotine), catecholmethyltransferase inhibitors (entacapone), and monoamine oxidase B inhibitors (rasagiline) have also been developed to provide more continuous oral delivery of dopaminergic stimulation in order to improve motor outcomes. Using dopamine agonists early, before levodopa, proved to delay the onset of dyskinesia, although this is achieved at the price of potentially disabling daytime somnolence or impulse control disorders. The demonstration of an antidyskinetic effect of the glutamate antagonist amantadine opened the door for novel nondopaminergic approaches of Parkinson's disease therapy. More recently, nonmotor symptoms (depression, dementia, and psychosis) have been the focus of the first randomized controlled trials in this field. Despite therapeutic advances, Parkinson's disease continues to be a relentlessly progressive disorder leading to severe disability. Neuroprotective interventions able to modify the progression of Parkinson's disease have stood out as a failed therapeutic goal over the last 2 decades, despite potentially encouraging results with compounds like rasagiline. Newer molecular targets, new animal models, novel clinical trial designs, and biomarkers to assess disease modification have created hope for future therapeutic interventions. © 2011 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus
Benabid, A. L., Pollak, P., Hoffmann, D., Gervason, C., Hommel, M., Perret, J. E., de Rougemont, J., & Gao, D. M. (1991) · The Lancet · doi:10.1016/0140-6736(91)91175-t · Cited by 1,787
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citationSydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Sleepiness in Parkinson's disease: A controlled study
Brodsky, M. A., Godbold, J., Roth, T., & Olanow, C. W. (2003) · Movement Disorders · doi:10.1002/mds.10429 · Cited by 169
Parkinson's disease: opportunities for novel therapeutics to reduce the problems of levodopa therapy
FOX, S., CHUANG, R., & BROTCHIE, J. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00923-0 · Cited by 39
Cited by
On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
Hacksell, U., Burstein, E. S., McFarland, K., Mills, R. G., & Williams, H. (2014) · Neurochemical Research · doi:10.1007/s11064-014-1293-3 · Cited by 297
Whone, A., Luz, M., Boca, M., Woolley, M., Mooney, L., Dharia, S., Broadfoot, J., Cronin, D., Schroers, C., Barua, N. U., et al. (2019) · Brain · doi:10.1093/brain/awz023 · Cited by 282
Bagetta, V., Sgobio, C., Pendolino, V., Del Papa, G., Tozzi, A., Ghiglieri, V., Giampà, C., Zianni, E., Gardoni, F., Calabresi, P., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2664-12.2012 · Cited by 74
“These agonists constitute a powerful clinical option, showing several advantages, such as direct receptor stimulation without metabolic modifications (required for L-DOPA) and prolonged pharmacological action (Rascol et al., 2011).”
BackgroundRaket, L. L., Oudin Åström, D., Norlin, J. M., Kellerborg, K., Martinez-Martin, P., & Odin, P. (2022) · Scientific Reports · doi:10.1038/s41598-021-04356-8 · Cited by 72
Tian, J., Du, G., Ye, L., Yu, X., Zhang, J., Wang, H., Yu, P., Fu, F., Liu, W., Li, Y., et al. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.11.010 · Cited by 15
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats
Ye, L., Guan, X., Tian, J., Zhang, J., Du, G., Yu, X., Yu, P., Cen, X., Liu, W., & Li, Y. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.02.015 · Cited by 14
Metadata
- Authors
- Rascol, O., Lozano, A., Stern, M., & Poewe, W.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2011-05
- Volume
- 26
- Issue
- 6
- Pages
- 1072-1082
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2082868177
- Cited by
- 198
- References
- 7
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.